Angel M Sevillano1,2, Monserrat Diaz3, Fernando Caravaca-Fontán1,2, Clara Barrios4, Carmen Bernis5, Jimena Cabrera6, Jesus Calviño7, Lorena Castillo8, Carmen Cobelo7, Patricia Delgado-Mallén9, Mario Espinosa10, Gema Fernandez-Juarez11, Maria Jose Fernandez-Reyes12, Rosa Garcia-Osuna13, Patricia Garcia14, Marian Goicoechea15, Fayna Gonzalez-Cabrera16, Diomaris A Guzmán17, Manuel Heras12, Guillermo Martín-Reyes17, Alberto Martinez8, Teresa Olea18, Jessy Korina Peña19, Luis F Quintana20, Cristina Rabasco10, Katia López Revuelta11, Lida Rodas20, Nuria Rodriguez-Mendiola21, Eva Rodriguez4, Luz San Miguel3, Maria Dolores Sanchez de la Nieta22, Amir Shabaka23, Milagros Sierra24, Alfonso Valera14, Mercedes Velo23, Eduardo Verde15, Jose Ballarin3, Oscar Noboa25, Juan Antonio Moreno26, Eduardo Gutiérrez1, Manuel Praga27,2. 1. Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain. 2. Department of Medicine, Complutense University, Madrid, Spain. 3. Department of Nephrology, Fundación Puigvert, Barcelona, Spain. 4. Department of Nephrology, Hospital del Mar, Barcelona, Spain. 5. Department of Nephrology, Hospital Universitario de La Princesa, Madrid, Spain. 6. Programa de prevención y tratamiento de las glomerulopatias (PPTG) de Uruguay, Sociedad Uruguaya de Nefrologia Centro de Nefrología, Hospital de Clinicas Montevideo, Montevideo, Uruguay. 7. Department of Nephrology, Hospital de Lucus Augusti, Lugo, Spain. 8. Department of Nephrology, Hospital Universitario Joan XXIII, Tarragona, Spain. 9. Department of Nephrology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. 10. Department of Nephrology, Hospital Universitario Reina Sofia, Cordoba, Spain. 11. Department of Nephrology, Hospital Universitario Fundación Alcorcón, Alcorcon, Spain. 12. Department of Nephrology, Hospital General de Segovia, Segovia, Spain. 13. Department of Nephrology, Hospital de Palamós, Palamos, Spain. 14. Department of Nephrology, Hospital Virgen de la Victoria, Malaga, Spain. 15. Department of Nephrology, Hospital Universitario Gregorio Marañón, Madrid, Spain. 16. Department of Nephrology, Hospital Universitario de Gran Canaria Dr. Negrin, Gran Canaria, Spain. 17. Department of Nephrology, Hospital Regional Universitario de Málaga, Malaga, Spain. 18. Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain. 19. Department of Nephrology, Hospital Principe de Asturias, Alcala de Henares, Spain. 20. Department of Nephrology, Hospital Clinic de Barcelona, Barcelona, Spain. 21. Department of Nephrology, Hospital Universitario Ramón y Cajal, Madrid, Spain. 22. Department of Nephrology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain. 23. Department of Nephrology, Hospital Clínico de Madrid, Madrid, Spain. 24. Department of Nephrology, Hospital San Pedro, Logrono, Spain. 25. Nephrology Center, Hospital de Clínicas, Department of Medicine, Republic University, Montevideo, Uruguay; and. 26. Department of Cell Biology, Physiology, and Immunology, Maimonides Biomedical Research Institute of Cordoba, University of Cordoba, Cordoba, Spain. 27. Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain; mpragat@senefro.org.
Abstract
BACKGROUND AND OBJECTIVES: Some studies suggest that the incidence of IgA nephropathy is increasing in older adults, but there is a lack of information about the epidemiology and behavior of the disease in that age group. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this retrospective multicentric study, we analyzed the incidence, forms of presentation, clinical and histologic characteristics, treatments received, and outcomes in a cohort of 151 patients ≥65 years old with biopsy-proven IgA nephropathy diagnosed between 1990 and 2015. The main outcome was a composite end point of kidney replacement therapy or death before kidney replacement therapy. RESULTS: We found a significant increase in the diagnosis of IgA nephropathy over time from six patients in 1990-1995 to 62 in 2011-2015 (P value for trend =0.03). After asymptomatic urinary abnormalities (84 patients; 55%), AKI was the most common form of presentation (61 patients; 40%). Within the latter, 53 (86%) patients presented with hematuria-related AKI (gross hematuria and tubular necrosis associated with erythrocyte casts as the most important lesions in kidney biopsy), and eight patients presented with crescentic IgA nephropathy. Six (4%) patients presented with nephrotic syndrome. Among hematuria-related AKI, 18 (34%) patients were receiving oral anticoagulants, and this proportion rose to 42% among the 34 patients older than 72 years old who presented with hematuria-related AKI. For the whole cohort, survival rates without the composite end point were 74%, 48%, and 26% at 1, 2, and 5 years, respectively. Age, serum creatinine at presentation, and the degree of interstitial fibrosis in kidney biopsy were risk factors significantly associated with the outcome, whereas treatment with renin-angiotensin-aldosterone blockers was associated with a lower risk. Immunosuppressive treatments were not significantly associated with the outcome. CONCLUSIONS: The diagnosis of IgA nephropathy among older adults in Spain has progressively increased in recent years, and anticoagulant therapy may be partially responsible for this trend. Prognosis was poor. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_07_16_CJASNPodcast_19_08_.mp3.
BACKGROUND AND OBJECTIVES: Some studies suggest that the incidence of IgA nephropathy is increasing in older adults, but there is a lack of information about the epidemiology and behavior of the disease in that age group. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this retrospective multicentric study, we analyzed the incidence, forms of presentation, clinical and histologic characteristics, treatments received, and outcomes in a cohort of 151 patients ≥65 years old with biopsy-proven IgA nephropathy diagnosed between 1990 and 2015. The main outcome was a composite end point of kidney replacement therapy or death before kidney replacement therapy. RESULTS: We found a significant increase in the diagnosis of IgA nephropathy over time from six patients in 1990-1995 to 62 in 2011-2015 (P value for trend =0.03). After asymptomatic urinary abnormalities (84 patients; 55%), AKI was the most common form of presentation (61 patients; 40%). Within the latter, 53 (86%) patients presented with hematuria-related AKI (gross hematuria and tubular necrosis associated with erythrocyte casts as the most important lesions in kidney biopsy), and eight patients presented with crescentic IgA nephropathy. Six (4%) patients presented with nephrotic syndrome. Among hematuria-related AKI, 18 (34%) patients were receiving oral anticoagulants, and this proportion rose to 42% among the 34 patients older than 72 years old who presented with hematuria-related AKI. For the whole cohort, survival rates without the composite end point were 74%, 48%, and 26% at 1, 2, and 5 years, respectively. Age, serum creatinine at presentation, and the degree of interstitial fibrosis in kidney biopsy were risk factors significantly associated with the outcome, whereas treatment with renin-angiotensin-aldosterone blockers was associated with a lower risk. Immunosuppressive treatments were not significantly associated with the outcome. CONCLUSIONS: The diagnosis of IgA nephropathy among older adults in Spain has progressively increased in recent years, and anticoagulant therapy may be partially responsible for this trend. Prognosis was poor. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_07_16_CJASNPodcast_19_08_.mp3.
Authors: Juan Antonio Moreno; Catalina Martín-Cleary; Eduardo Gutiérrez; Alfonso Rubio-Navarro; Alberto Ortiz; Manuel Praga; Jesús Egido Journal: Nephrol Dial Transplant Date: 2012-01 Impact factor: 5.992
Authors: Daniel C Cattran; Rosanna Coppo; H Terence Cook; John Feehally; Ian S D Roberts; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Chi Bon Leung; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang Journal: Kidney Int Date: 2009-07-01 Impact factor: 10.612
Authors: Sergey V Brodsky; Anjali Satoskar; Jun Chen; Gyongyi Nadasdy; Jeremiah W Eagen; Mirza Hamirani; Lee Hebert; Edward Calomeni; Tibor Nadasdy Journal: Am J Kidney Dis Date: 2009-07-04 Impact factor: 8.860
Authors: Hernando Trujillo; Justo Sandino; Teresa Cavero; Fernando Caravaca-Fontán; Eduardo Gutiérrez; Ángel M Sevillano; Amir Shabaka; Gema Fernández-Juárez; Pablo Rodríguez Doyágüez; Rocío Gimena Muñoz; Leonardo Calle García; Virginia Cabello; José Manuel Muñoz-Terol; Ana García Santiago; Oscar Toldos; Juan Antonio Moreno; Manuel Praga Journal: Kidney Int Rep Date: 2022-01-19